Also during ASH 2019, Dr. Koffman interviewed Dr. Adrian Wiestner, who discussed bi-specific antibodies to improve the immune system in CLL patients. There is reason to believe that when used in combination with a BTK inhibitor such as ibrutinib, they would have increased effectiveness, as ibrutinib improves T cell